Literature DB >> 8958804

Von Hippel-Lindau tumour suppressor gene. Localization of expression by in situ hybridization.

Y Nagashima1, Y Miyagi, K Udagawa, A Taki, K Misugi, N Sakai, K Kondo, S Kaneko, M Yao, T Shuin.   

Abstract

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene is responsible not only for VHL disease, but also for sporadic renal cell carcinoma and cerebellar haemangioblastoma. The distribution of VHL gene expression in the mouse embryo was recently studied by in situ hybridization, along with human VHL in 14-week-old fetal kidney: there was widely distributed expression in the former and expression in the tubules and blastema in the latter. Adult human tissue and other fetal organs were not examined. The present paper describes an in situ hybridization study to assess the function of the VHL gene in adult human tissues and in tissues of human fetus at 28 weeks of gestation. The expression of the VHL gene was limited to the adult and fetal brain and kidney, and the adult prostate. Nerve cells in adult and fetal brain were positive, including the cerebellar Purkinje cells. In adult and fetal kidney, the proximal tubular epithelium, the putative origin of the common type of renal cell carcinoma, showed intense signal, whereas the distal nephron, glomeruli, and nephrogenic blastema showed no significant signal. The prostate showed significant signal in the basal epithelium. The adrenal, pancreas, and epidydimis showed no significant signal, in spite of the frequent occurrence at these sites of neoplastic or hamartomatous lesions in VHL disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958804     DOI: 10.1002/(SICI)1096-9896(199611)180:3<271::AID-PATH664>3.0.CO;2-2

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  5 in total

Review 1.  The molecular basis of von Hippel-Lindau disease.

Authors:  O Iliopoulos; W G Kaelin
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

2.  Acute inactivation of the VHL gene contributes to protective effects of ischemic preconditioning in the mouse kidney.

Authors:  Mitsuko Iguchi; Yoshihiko Kakinuma; Atsushi Kurabayashi; Takayuki Sato; Taro Shuin; Seung-Beom Hong; Laura S Schmidt; Mutsuo Furihata
Journal:  Nephron Exp Nephrol       Date:  2008-10-27

3.  EAF2 loss enhances angiogenic effects of Von Hippel-Lindau heterozygosity on the murine liver and prostate.

Authors:  Laura E Pascal; Junkui Ai; Lora H Rigatti; Anne K Lipton; Wuhan Xiao; James R Gnarra; Zhou Wang
Journal:  Angiogenesis       Date:  2011-06-03       Impact factor: 9.596

4.  CUL2-mediated clearance of misfolded TDP-43 is paradoxically affected by VHL in oligodendrocytes in ALS.

Authors:  Tsukasa Uchida; Yoshitaka Tamaki; Takashi Ayaki; Akemi Shodai; Seiji Kaji; Toshifumi Morimura; Yoshinori Banno; Kazuchika Nishitsuji; Naomi Sakashita; Takakuni Maki; Hirofumi Yamashita; Hidefumi Ito; Ryosuke Takahashi; Makoto Urushitani
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

5.  Pathological and Clinical Features and Management of Central Nervous System Hemangioblastomas in von Hippel-Lindau Disease.

Authors:  Hiroshi Kanno; Natsuki Kobayashi; Satoshi Nakanowatari
Journal:  J Kidney Cancer VHL       Date:  2014-08-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.